相似文献
1
Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?
Cancer Immunol Immunother. 2008 Oct;57(10):1531-9. doi: 10.1007/s00262-008-0501-x. Epub 2008 Mar 15.
2
Tumor-host immune interactions and dendritic cell dysfunction.
Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7.
3
Strategies for tumor immune escape.
Drugs Today (Barc). 2003 Sep;39(9):701-24. doi: 10.1358/dot.2003.39.9.799478.
4
Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?
Langenbecks Arch Surg. 2008 Nov;393(6):995-1003. doi: 10.1007/s00423-007-0245-7. Epub 2007 Dec 4.
5
Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.
Cancer Immunol Immunother. 2007 Nov;56(11):1687-700. doi: 10.1007/s00262-007-0343-y. Epub 2007 Jun 15.
6
Suppression, subversion and escape: the role of regulatory T cells in cancer progression.
Clin Exp Immunol. 2013 Jan;171(1):36-45. doi: 10.1111/j.1365-2249.2012.04657.x.
7
From tumor cell metabolism to tumor immune escape.
Int J Biochem Cell Biol. 2013 Jan;45(1):106-13. doi: 10.1016/j.biocel.2012.04.024. Epub 2012 May 5.
8
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Science. 2011 Mar 25;331(6024):1565-70. doi: 10.1126/science.1203486.
9
Tumor associated regulatory dendritic cells.
Semin Cancer Biol. 2012 Aug;22(4):298-306. doi: 10.1016/j.semcancer.2012.02.010. Epub 2012 Mar 6.
10
[Immune response and cancer].
Bull Cancer. 2008 Jan;95(1):57-67. doi: 10.1684/bdc.2008.0558.
引用本文的文献
1
Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
Clin Exp Med. 2017 Feb;17(1):19-31. doi: 10.1007/s10238-015-0394-x. Epub 2015 Oct 8.
2
The emerging understanding of myeloid cells as partners and targets in tumor rejection.
Cancer Immunol Res. 2015 Apr;3(4):313-9. doi: 10.1158/2326-6066.CIR-15-0041.
3
Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study.
BJU Int. 2015 Feb;115(2):238-47. doi: 10.1111/bju.12641. Epub 2014 Mar 26.
4
Immune cells in the normal ovary and spontaneous ovarian tumors in the laying hen (Gallus domesticus) model of human ovarian cancer.
PLoS One. 2013 Sep 9;8(9):e74147. doi: 10.1371/journal.pone.0074147. eCollection 2013.
5
HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer.
PLoS One. 2012;7(12):e51301. doi: 10.1371/journal.pone.0051301. Epub 2012 Dec 19.
6
A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo.
Int J Cancer. 2013 Mar 1;132(5):1213-21. doi: 10.1002/ijc.27756. Epub 2012 Aug 24.
7
Nerve-cancer interactions in the stromal biology of pancreatic cancer.
Front Physiol. 2012 Apr 17;3:97. doi: 10.3389/fphys.2012.00097. eCollection 2012.
8
Autoantibodies to mesothelin in infertility.
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1970-8. doi: 10.1158/1055-9965.EPI-11-0139. Epub 2011 Aug 16.
9
Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.
Cancer Immunol Immunother. 2012 Jan;61(1):19-29. doi: 10.1007/s00262-011-1077-4. Epub 2011 Aug 7.
10
Macrophage infiltration predicts a poor prognosis for human ewing sarcoma.
Am J Pathol. 2011 Sep;179(3):1157-70. doi: 10.1016/j.ajpath.2011.05.034. Epub 2011 Jul 21.
本文引用的文献
1
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.
Nat Med. 2008 Jan;14(1):28-36. doi: 10.1038/nm1699. Epub 2008 Jan 6.
2
Adaptive immunity maintains occult cancer in an equilibrium state.
Nature. 2007 Dec 6;450(7171):903-7. doi: 10.1038/nature06309. Epub 2007 Nov 18.
3
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
Cell. 2007 Nov 2;131(3):463-75. doi: 10.1016/j.cell.2007.08.038.
4
Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors.
Nat Med. 2007 Oct;13(10):1211-8. doi: 10.1038/nm1649. Epub 2007 Sep 30.
5
Do autochthonous tumors interfere with effector T cell responses?
Semin Cancer Biol. 2007 Aug;17(4):267-74. doi: 10.1016/j.semcancer.2007.06.007. Epub 2007 Jun 23.
6
Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.
Cancer Immunol Immunother. 2007 Nov;56(11):1687-700. doi: 10.1007/s00262-007-0343-y. Epub 2007 Jun 15.
7
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.
Cancer Cell. 2007 Mar;11(3):291-302. doi: 10.1016/j.ccr.2007.01.012.
8
Humoral immunity, inflammation and cancer.
Curr Opin Immunol. 2007 Apr;19(2):209-16. doi: 10.1016/j.coi.2007.01.001. Epub 2007 Feb 2.
9
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.
Cancer Cell. 2006 Nov;10(5):437-49. doi: 10.1016/j.ccr.2006.09.013.
10
Interferons, immunity and cancer immunoediting.
Nat Rev Immunol. 2006 Nov;6(11):836-48. doi: 10.1038/nri1961.
Zotero 插件